Krystal Biotech, Inc.
KRYS
$256.33
$6.172.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 204.83M | 198.91M | 146.73M | 123.96M | 89.16M |
| Total Depreciation and Amortization | 2.45M | 2.14M | 2.16M | 3.14M | 3.21M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.00M | 26.73M | 52.02M | 50.69M | 45.50M |
| Change in Net Operating Assets | -36.42M | -51.58M | -5.51M | -39.29M | -14.46M |
| Cash from Operations | 200.87M | 176.20M | 195.40M | 138.50M | 123.42M |
| Capital Expenditure | -11.95M | -10.61M | -9.96M | -9.18M | -4.24M |
| Sale of Property, Plant, and Equipment | 435.00K | 435.00K | 435.00K | 435.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -46.90M | -143.18M | -173.88M | -183.48M | -159.20M |
| Cash from Investing | -58.42M | -153.36M | -183.40M | -192.23M | -163.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 22.66M | 9.40M | 9.05M | 17.89M | 32.40M |
| Repurchase of Common Stock | -13.96M | -13.93M | -13.93M | -13.93M | -5.39M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.71M | -4.53M | -4.88M | 3.97M | 27.01M |
| Foreign Exchange rate Adjustments | 286.00K | 329.00K | 922.00K | -474.00K | -458.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 151.44M | 18.64M | 8.04M | -50.24M | -13.46M |